This year's report features a special section on cancer survival.
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T he American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate each year to produce an annual report to the nation regarding the current status of cancer in the U.S. The initial report in 1998 documented the first sustained decline in cancer death rates since national record-keeping was instituted in the 1930s. 1 Subsequent reports generally confirmed this finding and provided updates. [2] [3] [4] [5] [6] Last year's report focused on the use of surveillance data for cancer control. The current report provides incidence and mortality data for all cancers and the top 15 cancers among all races combined and in each major racial/ethnic population (whites, blacks, Asians/Pacific Islanders [API], American Indians/Alaska Natives [AI/AN], and Hispanics/ Latinos). It also features a special section concerning cancer survival over time and by race/ethnicity (non-Hispanic whites, Hispanic whites, blacks, API, and AI/AN).
MATERIALS AND METHODS

Cancer Cases and Deaths
Information regarding newly diagnosed cancer cases in the U.S. is based on data collected by cancer registries participating in the NCI's Surveillance, Epidemiology, and End Results (SEER) Program or the CDC's National Program of Cancer Registries (NPCR). All registries are members of the NAACCR. 7 With the exception of bladder cancer, the data regarding incidence refer to invasive but not in situ cancers. Beginning with incident cases in 2001, all information concerning primary cancer site and histology was coded ac-cording to the third edition of the International Classification of Diseases for Oncology (ICD-O) 8 and categorized according to SEER site groups. 9 To ensure as much comparability as possible between the second and third revisions of the ICD-O, the following inclusions/exclusions were made: borderline tumors of the ovary, refractory anemias, and other myelodysplastic syndromes were excluded, whereas pilocytic astrocytomas were included. The site/histology categories presented for childhood survival are based on site first and then histology to be more comparable to the adult cancers; therefore, this listing is not equivalent to the International Classification of Childhood Cancer. 10 We defined childhood as age Ͻ 20 years. When applicable, cancer cases were staged as either localized, regional, distant, or unknown according to SEER Summary Stage 1977. 11, 12 Cases identified by death certificate or autopsy only were excluded from staging and survival.
Cancer deaths in the U.S., reported to state vital statistics offices and consolidated into a database by the CDC, through the National Vital Statistics System, 13 were coded according to the version of the International Classification of Diseases (ICD) in use in the U.S. at the time of death. 14 -16 Beginning with 1999 mortality data, the tenth revision of the ICD (ICD-10) was used to code the cause of death. Under ICD-10 rules, cancer was slightly more likely to be selected as the underlying cause of death than under previous ICD rules. 17 Sites were grouped by SEER to allow for maximum comparability between versions of ICD codes. 9 For the long-term trend analyses of the rates for all cancers and the 15 most common cancers among all races/ethnicity combined, we used SEER incidence data from the 9 original registries (covering approximately 10% of the U.S. population) 18 and U.S. mortality data for . For the short-term trend analyses of the incidence and death rates for the 15 most common cancers in each major racial and ethnic population (whites, blacks, API, AI/AN, and Hispanics/ Latinos), we used incidence data from 12 SEER cancer registries (covering approximately 14% of the U.S. population, including 12% of whites, 12% of blacks, 36% of API, 21% of AI/AN, and 22% of Hispanics/ Latinos) and 100% of the U.S. population for cancer mortality data for 1992-2001. We examined incidence data for 23 cancers and mortality data for 22 cancers to accommodate the top 15 cancers for incidence rates and for death rates in each racial and ethnic population. Information regarding cancer incidence and death is collected on groups within the API and Hispanic/Latino populations but rates cannot be calculated because of the lack of intercensal county population estimates from the U.S. Census Bureau. Changes in survival rates over time were examined for the top 15 cancers in males and females and for cancers common in children and adolescents (ages birth-19 years) using cancer cases diagnosed during 1975-1979 and 1995-2000 in the 9 SEER areas. For describing and comparing cancer survival rates among racial and ethnic populations, cancer cases diagnosed between 1992-2000 in the 12 SEER areas were used. For assessing geographic variations in stage distribution for cancers of the colon/rectum, female breast, cervix uteri, and prostate, we used incidence data reported to the NAACCR from 29 SEER and NPCR registries for 1996 -2000 that met NAACCR criteria for high quality incidence data as of December 2003, covering 43% of the U.S. population.
Cancer Incidence and Death Rates
Rates were age-adjusted to the 2000 U.S. standard million population and expressed per 100,000 populations by use of population estimates from the U.S. Census Bureau. Estimates of rates, standard errors, and 95% confidence intervals were generated using SEER*Stat software. 18 
Statistical Analysis
The long-term trends in cancer incidence and death rates among all races combined were described by joinpoint regression analysis, which involves fitting a series of joined straight lines on a log scale to the trends in the age-adjusted rates. 19 The resultant trends of varying time periods were described by annual percent change (i.e., the slope of the line segment). We present the incidence trends based on both the observed data and data with reporting adjustment. Reporting adjustment refers to the adjustment for the late arrival of new cancer cases to cancer registries after the standard reporting period for a diagnosis year as well as to changes and updates of data items such as demography and tumor characteristics for previously reported cases. This adjustment, which will be referred to as delay adjustment hereafter, is important because the most recent diagnosis year will have the largest underreporting of cases, with smaller amounts of underreporting for earlier diagnosis years. We use statistical models to adjust the current cancer count to account for anticipated future improvements to the data based on observed patterns in SEER registries. 20 Delay adjustment may affect the interpretation of current trends, especially for cancers frequently diagnosed in nonhospital settings such as melanoma, breast cancer, and prostate cancer. However, descriptions of long-term trends in the text are based on the observed data, except when specifically noted. For the short-term trend analyses in each racial and ethnic population, annual percent changes for a fixed time period (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) were estimated by fitting a linear regression line to the natural logarithms of the rates using calendar year as the independent variable. 3 In describing trends, the terms "increase" or "decrease" were used when the slope (coefficient) of the trend was statistically significant (two-sided P Ͻ 0.05) and the terms "stable" or "level" were used otherwise.
Changes in the 5-year relative survival rates for the top 15 cancers and childhood cancers were examined by a life table method for cases diagnosed between 1975-1979 and 1995-2000 and followed for vital status through December 31, 2001 . We compared survival rates between these two periods by calculating absolute (1995-2000 rate minus 1975-1979 rate) and proportional (absolute change divided by the 1975-1979 rate) changes. Survival rates by race/ethnicity for the 23 cancers were described using cancer-specific survival rates instead of relative survival rates because reliable expected life tables are not available for the Hispanic white, AI/AN, and API populations to generate valid relative survival estimates. The Kaplan-Meier estimator 21 was used to estimate the 5-year cancerspecific survival. Both relative and cause-specific survival rates provide an estimate of the likelihood of surviving 5 years if the index cancer was the only cause of death, although the estimation methods differ as described elsewhere. 22 Differences in cancer survival among racial and ethnic populations (with non-Hispanic whites as the reference group) were assessed by computing relative risks (RRs) (i.e., hazard ratios) of cancer death, after controlling for age (all sites, brain cancer, myeloma, and leukemia) or controlling for both age and tumor stage at the time of diagnosis (remaining sites) using Cox regression models, with a maximum of 5 years of follow-up. 23 Stratified Cox models were used to avoid the assumption of proportional hazards for age and tumor stage. SAS statistical software was used in the analysis, with two-sided P values Ͻ 0.05 considered to indicate statistical significance. 24 Note that the duration of survival was measured from date of diagnosis and that cases identified by death certificate or autopsy only were excluded from survival analyses because the survival duration was unknown or not applicable.
Additional data concerning cancer incidence and mortality are available from the following URL addresses: www.cancer.org (ACS); www.cdc.gov/cancer/ npcr/index.htm and www.cdc.gov/nchs/about/major/ dvs/mortdata.htm (CDC); and www.naaccr.org/CINAP/ index.htm (NAACCR).
RESULTS
Update on the Long-Term Incidence Trends for All Cancers Combined and the Top 15 Cancer Sites for All Races
Overall cancer incidence rates for all racial and ethnic populations combined declined by 0.5% per year between 1991-2001 but stabilized between 1995-2001 when adjusted for delay in reporting (Table 1) . Incidence rates for all cancers combined stabilized from 1995-2001 both in men and in women, but these rates increased in women by 0.3% per year since 1987 when adjusted for delay in reporting. For males, cancer incidence rates increased during the last time segment for prostate cancer, melanoma of the skin (melanoma), kidney and renal pelvis (kidney) cancer, and cancer of the esophagus and remained the same for urinary bladder (bladder) cancer, non-Hodgkin lymphoma (NHL), liver and intrahepatic bile duct (liver) cancer, and brain and other nervous system (brain) cancers. Incidence declined for the remaining top 15 cancer sites, which include lung and bronchus (lung), colon/rectum, oral cavity and pharynx (oral cavity), leukemia, stomach, pancreas, and larynx. When rates were adjusted for delayed reporting, the directions of trend changed, with a significant increase noted for bladder cancer and a stabilized trend for leukemia and pancreatic cancer reported. 
Incidence and Mortality by Race and Ethnicity (Whites, Blacks, API, AI/AN, and Hispanics/Latinos) between 1992-2001
The 15 most frequently occurring cancers by sex for incidence and mortality between 1992-2001 were ranked for all races combined and for each racial and ethnic population separately (Tables 3 and 4 ). Among men, cancers of the prostate, lung, and colon/rectum were the three most common incident cancers in rank order for every racial and ethnic population, except His- panics/Latinos, for whom colorectal cancer ranked ahead of lung cancer ( Table 3 ). The same three sites (with lung first and prostate second) were the leading causes of cancer death among men in each population, except in API men, in whom colon/rectum and liver cancers ranked second and third, respectively ( Table 4 ). Among women, the three leading cancer sites in rank order for incidence in each racial and ethnic population were breast, colon/rectum, and lung, except in white women, in whom lung cancer ranked second ( Table 3 ). The same three sites (with lung first and breast second) were the leading causes of cancer death among women in each population, except Hispanic/Latina women, whose death rates for breast cancer were higher than for cancer of the lung ( Table 4 ). Examination of short-term trends in incidence by race and ethnicity between 1992-2001 revealed that rates for lung and prostate cancer were decreasing among men in all populations, except API men (only lung decreasing); colorectal cancer rates were decreasing only for white and API men ( Table 3 ). Among females, breast cancer incidence rates were increasing in white and API women and were decreasing among AI/AN women; lung cancer rates also were decreasing in AI/AN women and were stable for the other populations.
Incidence trends for other cancer sites also varied by race/ethnicity and sex (Table 3) . Trends for many sites cannot be examined among AI/AN men and women because of small numbers; these sites are not noted in the results. Among men, declines in stomach cancer and nonepithelial skin cancers were observed in all populations; cancers of the oral cavity and larynx also were reported to decrease in all populations except among API men. Cervical cancer rates were reportedly decreasing for women of all racial and ethnic populations except AI/AN women (annual percent change ϭ -7.0; P Ͼ 0.05). Thyroid cancer rates were increasing among white, black, and Hispanic/Latina women, and kidney cancer increased among women of all racial and ethnic populations except among AI/AN women.
Analyses of short-term mortality trends revealed that death rates decreased in men for cancers of the lung, prostate, and colon/rectum in each racial and ethnic population, except for the lung in AI/AN men and the colon/rectum in AI/AN and Hispanic/Latino men ( Table 4 ). Among women, death rates decreased for colorectal cancer in white, black, and API women and for breast cancer in white, black and Hispanic/ Latina women, whereas rates increased for lung cancer in white women.
Mortality trends for cancer sites other than the top three sites also varied by race/ethnicity and sex (Table 4 ). Death rates for esophageal cancer increased among white men between 1992-2001 and decreased among black and Hispanic/Latino men. Stomach cancer death rates decreased in men and women of all racial and 
Cancer in the white population
Among women, white women had the highest cancer incidence rates for all cancer sites combined ( Table 3 ). The incidence rates for cancers of the female breast and bladder, NHL, melanoma, leukemia, brain cancer, cancer of the corpus uterus (corpus), cancer of the ovary, and cancer of the oral cavity (females only) were higher in white men and women than in other racial and ethnic populations, with melanoma rates being substantially higher. The rate of bladder cancer in white men (39.7 cases per 100,000 men) was nearly twice that of black men (20.2 cases). Of the top 15 causes of cancer deaths in white men and women, rates of lung cancer (women only), cancer of the ovary, bladder cancer (men only), NHL, leukemia, brain cancer, and melanoma were higher than in all other racial and ethnic populations (Table 4 ). 
Cancer in the black population
Among men, black men had the highest cancer incidence and death rates for all cancer sites combined and for cancers of the prostate, lung, colon/rectum, oral cavity, stomach (mortality only), kidney (incidence only), pancreas, esophagus, larynx, and myeloma (Tables 3  and 4 ). The age-adjusted rate of prostate cancer incidence in black men was 62% higher, and the death rate was more than twice that of white men, who have the second highest incidence and death rates of all racial and ethnic populations studied. Black women had the highest death rates for all sites combined and the highest incidence and death rates for the following sites: breast (mortality only), colon/rectum, lung (incidence only), kidney (incidence only), oral cavity (mortality only), pancreas, esophagus, myeloma, corpus (mortality only), cervix uteri (mortality only), and bladder (mortality only). The incidence and death rates for myeloma in black men and women were approximately double the rates for white men and women. Female breast cancer death rates were nearly 30% higher in the black population than in the white population, despite lower incidence rates.
Cancer in the API population
The incidence rates for cancers of the stomach, liver, and thyroid (women only) were higher in API populations than in other racial and ethnic populations. Cancer death rates were higher for cancers of the liver and stomach (women only). The liver cancer incidence rate for males was 20.7 compared with 13.1 for Hispanics/ Latinos, the population with the next highest rate.
Cancer in the AI/AN population
The death rate for kidney cancer in AI/AN men and women was higher than in other racial and ethnic populations. Although death rates from cancers of the liver and stomach among AI/AN men were lower than for other populations (with the exception of white men), these sites had ranks of 4 and 5, respectively, for cancer mortality among AI/AN men. Similarly, although the rates of ovarian cancer incidence in AI/AN women were lower than in other populations, ovarian cancer was the fifth most common cancer type in AI/AN women, the highest ranking for ovarian cancer in any racial or ethnic population.
Cancer in the Hispanic/Latino population
The incidence rates for cancers of the cervix uteri and gallbladder and the death rate for cancer of the gallbladder were higher in Hispanic/Latina women than among other racial and ethnic populations. The incidence rate for cancer of cervix uteri in this population (17.7) ranked 4th and was 38% higher than the rate for black women (12.8) , the population with the next highest rate.
Changes in Survival Rates over Time
The absolute and proportional changes in survival for cancer of all sites combined, all ages, was substantially greater for men than for women, although the current survival rates generally were similar ( (Table 6 ). Several sites with high survival rates (larynx and thyroid) and cancers of the corpus and cervix uteri showed little or no gain. Between 1975-1979 and 1995-2000, survival also improved for several less common cancers not listed in Table 5 , including testicular cancer (85-96%) and Hodgkin lymphoma (74 -85%).
Survival rates for childhood cancers demonstrated some of the largest improvements, with an absolute survival increase of 20% in boys and 13% in girls between 1975-1979 and 1995-2000 (Table 5 ). The 5-year relative survival rates in 1995-2000 varied according to type of cancer, from Ͻ 50% for acute myeloid leukemia in boys to Ͼ 95% for Hodgkin lymphoma in both boys and girls.
Stage-Specific Survival and Stage Distributions and Geographic Variations
For most specific cancers, patients diagnosed at an earlier stage of disease had higher 5-year survival rates than those diagnosed at more advanced stages in the 9 SEER areas ( Table 6 ). There were 9 cancer sites in which Ն 50% of cases were diagnosed at a localized stage, including the prostate, urinary bladder, melanoma, kidney, larynx, thyroid, breast, corpus, and cervix uteri. In contrast, the majority of lung (53%) and ovarian (68%) cancers were diagnosed at a distant stage.
The stage distributions for colorectal, breast, cervical, and prostate cancers are shown by state in Table 7 . The combined stage distributions for the 4 specific cancers among these 29 registries showed lower proportions of early stages and higher proportions of distant and unknown stages (Table 7 ) than those reported in the SEER Program (Table 6 ). Furthermore, the stage distributions varied by geographic area for each of the four cancers. The proportion of localized disease ranged from 28.5% in Nebraska to 44.4% in Hawaii for colorectal cancer, from 56.5% in Wyoming to 70.2% in Hawaii for female breast cancer, from 44.7% in Arizona to 62.5% in Utah for cervical cancer, and from 68.1% in Rhode Island to 95.5% in Utah for prostate cancer. The proportion of unknown stages of disease also varied by state for each of the four cancers. 
Survival Rates by Race and Ethnicity
For all cancers combined, cancer-specific survival rates at 5 years after diagnosis ranged from 53.9% (AI/AN) to 67.6% (non-Hispanic whites) among men and from 57.0% (blacks) to 68.7% (API) among women in the 5 racial/ethnic populations studied (Table 8 ). For both men and women, non-Hispanic white and API patients tended to have higher survival rates than their counterparts for the cancer sites examined, except non-Hispanic white patients, who had the lowest survival rates for cancer of the brain (33.5% for men and 35.1% for women) and API patients, who experienced the lowest survival rates for leukemia (39.1% for men and 38.9% for women). Adjusted RRs of cancer death, accounting for age or age and stage, were calculated using non-Hispanic white population as the reference group. Except for myeloma and cancers of the kidney, thyroid, and gallbladder for both sexes, melanoma and other nonepithelial skin cancers for men, and cancer of the liver for women, the overall test for racial/ethnic differences in risk of cancer death was statistically significant for each other cancer site examined and for all cancers combined. The risk of cancer death in every minority group was statistically significantly higher than that of non-Hispanic white patients for all cancers combined, except for API women, who had a similar risk of cancer death as their non-Hispanic white counterparts. Black men experienced 9 -67% higher adjusted risks of dying of the index cancer than non-Hispanic white men for 12 of 13 individual cancer sites with statistically significant racial/ethnic differences; black women experienced 7-82% higher adjusted risks for 12 of 14 such individual cancers, except for cancers of the brain (both sexes) and stomach (women), which were lower. Hispanic white and AI/AN patients generally had higher risks of dying from the index cancer than their non-Hispanic white and API counterparts. Both API men and women experienced the lowest RRs for each of the sex-specific major cancers (prostate, female breast, lung, and colon/rectum), with RRs ranging from 0.70 -0.95. In addition, API patients had the lowest RRs for cancers of the brain (women), liver (men), and pancreas (both sexes). However, non-Hispanic white men and women experienced the highest risks of brain cancer death whereas API men and women had the highest risks of leukemia death.
DISCUSSION
Overall Cancer Incidence, Mortality, and Survival Trends
The current study data show considerable progress in reducing the cancer burden in the U.S. Overall cancer death rates have continued to decrease since the early 1990s in both men and women and for many of the top 15 cancer sites, including lung, colon/rectum, and prostate in men and colon/rectum and breast in women. Overall incidence rates also have decreased, although they stabilized when adjusted for a delay in reporting. Survival rates have increased for many cancers over the last 20 years. The decrease in overall cancer death rates represents a change from last year's annual report, when the declines were reported to have leveled off in the most recent time period in women and both sexes combined. 6 With the additional data for 2001, it appears that the declines in mortality rates that began in the early 1990s are continuing, supporting an earlier interpretation that the apparent change in trend may be a consequence of changes in coding rules for underlying cause of death in the ICD-10, which were implemented with 1999 mortality data and revised population. 25 Changes in incidence may result from changes in the prevalence of risk factors and/or changes in detection practices due to the introduction or increased use of screening/diagnostic techniques. Furthermore, incidence trends can be affected by reporting delay. The overall trend in incidence for both sexes combined appears to have been heavily influenced by reporting delay and rapidly changing prostate cancer trends; prostate cancer decreased quickly between 1992-1995, after a period of rapid increase. When prostate cancer incidence rates were excluded from the trend analysis, the incidence rates for both sexes combined were stable during 1987-2001. Overall incidence rates also became stable between 1995-2001 when adjusted for reporting delay.
The gains in survival rates for all cancer sites combined and for the most common cancers over the last 20 years, which have been accompanied by decreases in death rates, may reflect improved treatment, earlier detection of cancers with effective treatments, and improved supportive and general medical care. However, the introduction of or improvements in early detection or diagnostic tests may increase observed survival rates spuriously by advancing the time of diagnosis of disease without prolonging life (lead-time bias), by the preferential detection of slower growing tumors (length-time bias), or by the detection of indolent cases that never would have been diagnosed in the absence of such diagnostic techniques (overdiagnosis bias). 9, 26, 27 Although examining temporal changes in disease stage at diagnosis and stage-specific survival may be helpful in understanding temporal trends in survival, they must be interpreted with caution because changes in stage-specific survival, especially for localized stage disease, also can be affected by lead-time, length-time, and overdiagnosis biases. 9, 26, 27 In addition, improvements in staging techniques or changes in staging systems can influence stage-specific survival. 28 Assessing the relative contribution of changes in disease detection, classification, and treatment is difficult when explaining temporal survival changes.
Survival rates for all cancers combined also may change over time or differ across racial and ethnic populations because of changes or differences in the mix of cancers. For example, the absolute change in survival for cancers of all sites in the last 20 years was substantially greater for men than for women. Much of the increase in survival for men reflects the increasing incidence and survival rate for prostate cancer during the period. When prostate cancer cases were excluded, the all cancers combined relative survival rate for men was 37.5% between 1975-1979 and 48.1% between 1995-2000, an absolute gain of 10% compared with approximately 20% with the inclusion of prostate cancer. The lower survival rate for men compared with women in the recent period, after the exclusion of prostate cancer, primarily results from a different mix of cancers, although women have a slight survival advantage for a number of cancers. The survival rate for a specific cancer also may be affected if there is variation by histologic type and the distribution of histologic types changes over time.
Differences in survival between racial and ethnic populations may be influenced by stage at diagnosis, the measurement biases discussed earlier, the prevalence of comorbidities, and the quality of cancer treatment and supportive care. Socioeconomic differences undoubtedly play a role; members of most racial and ethnic minorities are more likely to be poor, to have a lower level of income, and to lack health insurance compared with non-Hispanic white populations. 29 Historically, the prevalence of screening for breast, colorectal, and cervical cancers has been lower for members of racial and ethnic minorities compared with non-Hispanic white populations. 30 As a result, minority populations are more likely to be diagnosed at a more advanced stage of disease, when treatment is either not recommended or is less effective.
Differences in cause-specific survival rates by race and ethnicity may be influenced by differences in stage and age distribution; however, analyses of the RR of cancer death controlled for these factors. Even with control for stage, residual effects of screening, such as differences in the extent of disease within stage and lead-time, length-time, and overdiagnosis biases, may play a role. Other possible explanations for differential survival after a cancer diagnosis include socioeconomic barriers to timely and high-quality cancer care, cultural barriers and beliefs that may influence the treatment decision, and the presence of comorbidities. 29, [31] [32] [33] For many cancers, there are limited or no data available to explain survival differences, with much of the available data pertaining only to white and black patients. The limited data available frequently document differences in the receipt of optimal treatment based on socioeconomic status and race/ethnicity, with little evidence that response to treatment varies among racial and ethnic groups when accounting for stage of disease and other important prognostic variables. 33 The following sections describe possible reasons for temporal trends and variations in the incidence, mortality, and survival by race and ethnicity for the 4 common cancers and for cancers with an at least 10% absolute gain in the survival rate over the past 20 years in either men or women.
Prostate Cancer
The recent increase in prostate cancer incidence most likely reflects a return to baseline trends after a period of rapidly increasing, then decreasing, rates due to the introduction of the prostate-specific antigen (PSA) test. 34 Both PSA-related early detection and improved treatments may have contributed to the remarkable decreases in prostate cancer mortality noted since the early 1990s. 6 Reasons for the disproportionately higher prostate cancer incidence and death rates in black men compared with other racial ethnic populations are unknown. Age, race, and family history are the only well-documented risk factors. 35 Although one recent study linked agricultural chemical exposure to prostate cancer, 36 population-attributable risk differences in chemical exposure are unlikely to explain the large differences in prostate cancer incidence and death rates observed between black and white men.
The 5-year relative survival rate for prostate cancer increased significantly from 70% in the mid-1970s to 99% between 1995-2000, the largest absolute increase (29%) reported for any cancer. A shift in the detection of new prostate cancer cases from distantstage to early-stage disease through the widespread use of PSA testing has been reported 37 and most likely contributed to the improved survival. However, because a high proportion of men are found to have clinically occult cancer at autopsy, 38, 39 it is assumed that some prostate cancers identified by PSA would not have otherwise presented as clinical disease. 40 The extent to which overdiagnosis, length-time, and leadtime biases have contributed to improvements in survival is unknown, but believed to be substantial.
Improved survival from prostate cancer also may be due to the dissemination of hormonal therapy for early-stage and advanced stage disease. 41, 42 A recent pooled analysis of prostate cancer randomized trials found that the 10-year survival rate was significantly higher in men treated immediately with hormonal therapy (74%) compared with those who deferred such treatment (62%). 43 Substantial advances in radiation therapy techniques in the past decade also may have contributed to gains in survival. 44 The role of radical prostatectomy for localized disease has yet to be clarified.
After controlling for age and stage of diagnosis, the RR of cancer death once prostate cancer is diagnosed is highest for AI/AN men, followed by black and Hispanic white men; API men have a significantly lower risk than non-Hispanic white men. Low socioeconomic status, lack of health insurance, and low literacy rates can delay diagnosis and reduce access to optimal therapies. 45 Treatment differences such as a higher rate of radical prostatectomy for early-stage prostate cancer in white patients compared with black patients have been documented; 46 however, the impact on survival differences is unknown.
Lung Cancer
Changing temporal patterns in the occurrence of lung cancer are closely tied to historic cigarette smoking patterns, with the regular uptake of smoking and subsequent smoking reductions occurring later in women compared with men. 47 Among men, lung cancer incidence and mortality have been declining since the early 1980s and 1990s, respectively. In women, incidence rates have declined since 1998 and mortality rates have stabilized since 1995 for the first time, after increasing for several decades. This first-time decrease in the incidence rates in women in the SEER areas appears to be an early indication of the national trend because reductions in cigarette consumption started earlier in some areas covered by SEER compared with the other parts of the U.S. 48 Progress in the treatment of lung cancer has been extremely limited. 49, 50 Greater than 50% of cases are diagnosed at a distant stage, for which the 5-year relative survival is only 3.3% (Table 6) . Surgical resection may be curative for early-stage nonsmall cell lung cancer (NSCLC), with recent clinical studies showing improved survival with neoadjuvant chemotherapy. 49 With the exception of API patients, the RR of dying from lung cancer after diagnosis was 4 -23% higher in minority populations compared with non-Hispanic white patients. Differences in survival between black and white patients with NSCLC are largely explained by treatment differences, with 64.0% of black patients who are diagnosed at an early stage undergoing surgery compared with 76.7% of whites 51 and 28% of black patients diagnosed with metastatic disease receiving chemotherapy after seeing an oncologist compared with 35% of white patients. 52 In addition to ensuring equal access to high-quality treatment, improved survival from lung cancer may be achieved by earlier detection. Important research efforts include the National Lung Screening Trial, which has enrolled nearly 50,000 current or former smokers in a study to compare whether screening with spiral computed tomography or chest X-rays is better at reducing deaths from lung cancer (available from URL: http://www. nci.nih.gov/nlst).
Colorectal Cancer
Decreases in colorectal cancer incidence and mortality rates have been largely attributed to the detection and removal of precancerous polyps, the early detection of tumors through screening, and improved treatments. 4, 6 They also may reflect the increased use of hormone replacement therapy in women and antiinflammatory drugs, both of which appear to reduce the risk of colon cancer. 53, 54 A recent publication found a decreased risk of colorectal cancer but a more advanced stage of disease (increased lymph node and metastatic disease) among women receiving estrogen and progestin regimens. 55 The elevated incidence and death rates in the black population may reflect cultural and socioeconomic differences in physical inactivity, dietary habits, use of tobacco, and access to and utilization of preventive services. 56 From the mid-1970s until 1995-2000, the 5-year relative survival rate increased from 52% to 63% in women and from 50% to 64% in men, an increase that was second only to prostate cancer. The rate of colorectal screening remains low nationally (Ͻ 45% based on the 2000 National Health Interview survey 30 ) and the potential benefit with broader utilization has yet to be achieved. However, the use of colorectal screening is higher in non-Hispanic white men and women than in other racial and ethnic populations.
A significant advance in colorectal cancer treat-ment was the introduction of 5-fluoroucil-based adjuvant chemotherapy for patients with surgically resectable Stage III colon cancer in the late 1980s, which reduced mortality by as much as 30%. 57, 58 Lower rates of adjuvant therapy among black patients 59 -62 may contribute to differences in cancer survival. Other studies have documented disparities between black and non-Hispanic white patients with regard to the receipt of surgical and radiation treatments for colorectal cancer. 62, 63 
Female Breast Cancer
Recent increases in female breast cancer incidence reflect the increased use of mammography, 6, 64 and perhaps an increased prevalence of obesity and the use of hormone replacement therapy. 64 The steady decline in female breast cancer mortality since 1990 has been attributed, in part, to early detection 6 and the increased use of hormonal and adjuvant chemotherapies 65, 66 and the resulting improved survival, which increased by 13% since the mid-1970s.
Mammography screening increased in all segments of the U.S. population, although rates among minority populations lagged behind rates in white women. 30 White and API women are more likely to be diagnosed at a localized stage than women of other racial and ethnic populations. 67 Even when controlled for age and stage at diagnosis, black, Hispanic white, and AI/AN women had an increased RR of mortality after diagnosis compared with white and API women. Reasons for differential breast cancer survival between white and black women have been studied extensively. Several studies documented treatment differences between black and white women, 68 -70 and others found treatment and survival differences between black and white patients diminished when controlling for socioeconomic factors, such as lack of insurance coverage. 71, 72 Tumor and clinical characteristics such as estrogen receptor status, tumor size, tumor stage at diagnosis, and neutropenia also may influence the types and courses of treatment and survival, 64, [73] [74] [75] [76] although the differential availability of more biologically targeted treatment options also may contribute to variations in outcome.
Non-Hodgkin Lymphoma
NHL incidence trends partly reflect an increase in acquired immunodeficiency syndrome-associated NHL cases that began in the early 1980s and decreased in the 1990s. 77 The increased incidence in white compared with black populations in the U.S. precedes the rise in human immunodeficiency virus (HIV)-related NHL, and has remained remarkably consistent over time. 18 Recent declines in NHL mortality may reflect decreases in HIV-associated NHL incidence rates 77 and improved treatments. 78 NHL comprises a range of pathologic types with varying prognoses. 79, 80 Survival trends are influenced by the increase in HIV-related NHL cases, which have a poorer prognosis. 80 Nonetheless, modest gains in overall survival have been observed. Improved treatments for indolent NHL include radiotherapy for early-stage disease 81, 82 and single-agent and multiagent chemotherapy for advanced-stage disease. [83] [84] [85] For large cell lymphoma, an aggressive NHL, multiagent chemotherapy was shown in the 1970s and 1980s to achieve disease remission and long-term, disease-free survival in 35% of patients. 86, 87 More recently, rituximab, a monoclonal antibody directed against the CD20 antigen, was found to have activity against both indolent and aggressive NHL, 88 and autologous bone marrow transplantation was found to increase survival among patients with recurrent, aggressive NHL. 89, 90 Although all racial and ethnic minority groups have a higher RR of cancer death from NHL once diagnosed compared with non-Hispanic whites, no published study to date has assessed prognostic or treatment variations that may underlie these differences.
Melanoma
The continued increase in melanoma incidence rates may reflect increased recreational sun exposure as well as early detection, resulting mainly from increased awareness by health providers and the general public. 91 The markedly higher incidence and mortality for white patients reflects their enhanced susceptibility to the harmful effects of sun exposure. 92 The absolute gain in melanoma survival in males (12%) and females (6%) may be related both to early detection and improved treatment. Proportions and rates of melanomas diagnosed at a localized stage and as thin lesions have increased in the U.S. 91, 93 Surgical resection, the major curative therapy for melanoma at the current time, has undergone significant improvements as a result of documenting optimal margins based on the depth of the primary lesion. 94 The benefits of immunotherapy (interferon and interleukin-2) in recurrence-free survival and overall survival have been demonstrated in clinical trials, 95 and the use of recombinant interleukin-2 for patients with metastatic melanoma recently was approved. 96
Leukemia
The incidence of leukemia was stable for both males and females between 1975-1995, when rates began to decline for males only. Leukemia is more common in white populations than in other racial and ethnic groups, paralleling international patterns of increased incidence in Western and Northern Europe, North America, and Australia. Long-term decreases in leukemia death rates reflect dramatic improvements in survival from childhood leukemia, as well as modest improvements in survival for some leukemia subtypes in adults. Among children and adults combined, leukemia survival rose from 35.9% in 1975-1979 to 46.4% in 1995-2000 , whereas for leukemia patients diagnosed at age Ն 20 years, relative survival rates improved from 34% to 42%. 18 As a result of multiagent chemotherapy and central nervous system prophylaxis, relative survival for adult patients with acute lymphocyte leukemia (ALL) has improved from 11% in 1975-1979 to 28% in 1995-2000, 18,97,98 whereas survival among adults with chronic lymphocyte leukemia improved only slightly from the 1970s to the 1990s (69% vs. 73%). 18 Acute myeloid leukemia remains a highly fatal malignancy, although the 5-year relative survival improved from 6% to 17% over the last 20 years. Combined chemotherapy with daunorubicin and cytarabine remains the treatment of choice for most patients, 99 and improvements in survival may be attributed in part to improvements in supportive care, including the treatment of infections. 99 The 5-year relative survival for patients with chronic myelocytic leukemia (CML) also has increased. Historic treatment advances include chemotherapy with hydroxyurea and busulfan, and chemotherapy combined with interferon-␣. 100 More recent advances include allogeneic bone marrow transplant and treatment with imatinib mesylate, which has been demonstrated to be highly effective in inducing and sustaining disease remission when used as a first course of treatment. 101, 102 Survival improvements resulting from imatinib mesylate are too recent to be reflected in 1995-2000 statistics.
The RR of death among leukemia patients is markedly higher for all racial and ethnic minority populations compared with non-Hispanic white populations. The lowest survival rates observed in the API leukemia patients might be attributable to the 62% of API leukemia patients in SEER areas who were diagnosed with the more lethal subtypes of myeloid and monocytic leukemia compared with 44 -50% of other racial/ethnic populations. Treatment differences that may contribute to differential survival by race and ethnicity have not been studied. In the nine SEER areas, black, Hispanic, and AI/AN children with ALL have poorer survival than white and API children; 103 other reports have demonstrated that black children with ALL are more likely to present with unfavorable prognostic features. 104 However, in a single pediatric cancer hospital in which all patients received the same treatment without regard to ability to pay, black and white children had the same rate of survival and cure. 105 
Kidney Cancer
Reasons for the increasing incidence of kidney cancer are not clear, 106 but may reflect newer diagnostic techniques 107, 108 and an increased prevalence of obesity, 109, 110 which is a known risk factor for kidney cancer. 111 Despite the rising incidence, mortality rates have been stable since 1991 for men and since 1992 for women. Black men and women have the highest incidence rates among all racial and ethnic populations, but mortality rates are approximately equal for white and black populations and highest for AI/AN patients. Reasons for increased mortality among the AI/AN population are unknown. There is considerable variation in kidney cancer mortality in AI/AN persons by region, with death rates being particularly high in the Northern plains. 112 Approximately 50% of cancers of the kidney are diagnosed at the localized stage, for which the 5-year relative survival is Ͼ 90% ( Table 6 ). Surgery remains the primary treatment, with the benefit of adjuvant chemotherapy and radiotherapy considered to be unproven. 113 Improved survival may result in part from lowered surgical mortality rates due to advances in anesthesia and presurgical and postsurgical management. 113 When adjusted for age and stage of disease, no significant differences in the RRs of cancer death once diagnosed were noted between racial and ethnic groups.
Childhood Cancers
Since the introduction of chemotherapy for the treatment of childhood leukemia in the 1940s, the prognosis for childhood cancers has improved remarkably, from almost uniformly fatal before the mid-1960s to a 55% survival rate in the mid-1970s, to Ͼ 75% survival in the late 1990s. This improvement has been attributed to the success of chemotherapy for childhood ALL and the incorporation of chemotherapy into treatment regimens that previously relied on surgery or radiotherapy for common forms of childhood cancers such as Wilms' tumor, lymphoma, and osteosarcoma. 114 Increased survival from childhood cancers also may be correlated in part with improved quality of care through the pediatric cancer cooperative groups. Currently 70% of pediatric cancer patients age Ͻ 15 years receive their care in pediatric cancer treatment centers. 115 Although the 5-year survival has improved remarkably for most childhood cancers over the past two decades, with nearly all children with Hodgkin lymphoma surviving their disease, the survival rate is still low (Ͻ 50%) for some childhood cancers such as acute myeloid leukemia, reflecting a need for an improved understanding of the mechanism of resistance to therapy. 116 Age-specific analyses demonstrated that survival rates did not vary by age for all sites combined, but some variations were evident for individual sites. For example, the survival rates for ALL were 91% for patients ages 1-4 years but only approximately 60% for infants and patients ages 15-19 years. This may in part be related to the lower enrollment rates of adolescents and young adults in clinical trails compared with that of children. 117 In general, survival rates improved more for boys than girls, removing much of the advantage in girls' overall survival noted between 1975-1979.
Variations in Disease Stage at Diagnosis by Cancer Registry
Geographic variation in the stage of disease at diagnosis was most evident for cancers of the colon/rectum, cervix, and prostate, whereas much less variation was noted for female breast cancer. The percentages in Table 7 are not adjusted for age, which may influence stage distribution. Other differences in cancer stage at diagnosis may be related to differences in the population composition by race, ethnicity, 118,119 socioeconomic status, 120 -123 and health insurance status, 124, 125 all of which can influence access to and utilization of cancer screening services. As was discussed in last year's Annual Report to the Nation, the prevalence of mammography and cervical and colorectal cancer screening at recommended intervals also varies across the states. 6 Marked variation among states was noted in the percentage of unstaged cases for all four cancers. These variations could be related to differences in medical practice, varying socioeconomic characteristics in the population, registry operations, or a combination of these factors. It is important to better understand the reasons for these differences because inadequate staging may result in suboptimal treatment.
Limitations
There are certain limitations in the data and methods that may influence the interpretations of the findings in this report. First, routinely collected statistics regarding cancer occurrence, as provided in this analysis, are commonly reported according to the major racial and ethnic populations-whites, blacks, APIs, AI/ANs, and Hispanics/Latinos. Such broad racial and ethnic groupings may mask wide variations in the cancer burden by country of origin, for example, among APIs (China, Japan, Philippines, Vietnam, etc.) 126, 127 and Hispanics/Latinos (Spain, Cuba, Puerto Rico, Mexico, etc.) 128, 129 and by cultural characteristics that define other high-risk populations such as white residents in Appalachia, 130 recent immigrants, blacks in the rural South, and over 560 American Indian tribes recognized by individual states and the federal government. 112, [131] [132] [133] Cancer rates for populations other than whites and blacks may be limited by problems in ascertaining race/ethnicity information from basic records (medical records, death certificates, and census reports). 134, 135 Furthermore, the assessment of long-term cancer trends is limited to white and black populations because annual population counts for other racial and ethnic populations are not available prior to 1990.
Second, the survival data and most of the incidence data presented in this report are taken from the SEER registries. The SEER registries were selected to be a reasonably representative subset of the U.S. population, with a higher representation of racial and ethnic minorities. Therefore, cancer statistics generated from SEER areas may differ in some respects from cancer statistics throughout the country because SEER areas tend to have more foreign-born individuals and be more urban populations compared with non-SEER areas. 136 Third, we used two different statistical methods to describe cancer trends. A single linear model was used to describe short-term trends (1992-2001) in cancer incidence and death rates by race and ethnicity. In contrast, long-term patterns for all races and ethnicities combined were characterized using the joinpoint method. Analyses of data by these two approaches may in some circumstances lead to different results. For example, the prostate cancer incidence rate decreased by 2.5% per year from 1992-2001, whereas in the joinpoint model it increased by 1.4% per year from 1995-2001, after an 11.4% per year decrease from 1992-1995. The joinpoint model is a more flexible and accurate approach to identify the years in which significant changes in trends occurred, but cannot always be employed for analyses of trends by race and ethnicity because of the limited time period with available data.
Future Directions
The long-term goals of basic and clinical research, cancer surveillance, and cancer control are activities to eliminate suffering and death from cancer. This will come about by striving to prevent the onset as well as the progression of cancer; identifying cancers at the earliest stage of disease; eliminating cancer through targeted treatments; and controlling cancers that can-not be eliminated so they become manageable, chronic diseases.
Considerable reduction in the suffering and death from cancer in the U.S. could be achieved by reaching all segments of the population with high-quality prevention, early detection, and treatment services. 137 Disparities in access to and quality of care have been documented throughout the cancer spectrum. For example, the uninsured and those with only Medicare or Medicaid may lack access to effective smoking cessation therapies. 137 Individuals with low incomes, those without health insurance, and those who immigrated to the U.S. within the last 10 years have a lower prevalence of mammography and colorectal and Papanicolaou smear testing than other population groups. 30 Geographic variations also exist in the utilization of recommended screening tests 6 and in the stage of disease at diagnosis for cancers that are detectable by screening ( Table 7 ). In response to the documentation of healthcare disparities for racial and ethnic minorities and other medically underserved groups, federal programs targeted at reducing disparities have been created and strengthened. For example, the Quality of Cancer Care Committee (QCCC), organized by NCI in 2000, has sponsored several interagency projects to examine how the best available scientific evidence concerning intervention effectiveness can inform federal-level decision making regarding cancer care. In one QCCC project, three federal agencies (the NCI, the CDC, and the Health Resources and Services Administration) are collaborating with the nonprofit Institute for Healthcare Improvement to enhance screening and follow-up care for patients with breast, cervical, and colorectal cancers in community health centers for the medically underserved. 139 The National Breast and Cervical Cancer Early Detection Program created by the CDC in 1991 has provided over 4 million screening examinations to underserved women. However, estimates are that this program reaches only 12-15% of eligible women nationally. 140 In 2000, the NIH established the National Center on Minority Health and Health Disparities to lead and coordinate NIH efforts to improve the health of minority and medically underserved people. In 2001, the Center to Reduce Cancer Health Disparities was created within the NCI to stimulate research to address cancer health disparities.
There also has been growing recognition of gaps in the delivery of high-quality cancer care in recent years. 31 In 1999, the National Cancer Policy Board issued a comprehensive report on the state of the cancer care system, which concluded that some individuals with cancer do not receive care known to be effective for their condition. 138 Recommendations in-cluded the development and use of evidence-based guidelines for all aspects of cancer care; the development of a core set of quality measures that can be used to measure and monitor the quality of care; the enhancement of services for the uninsured and underinsured to ensure entry to, and equitable treatment within, the cancer care system; and research to understand why specific segments of the population do not receive appropriate care. Partnerships to nurture an integrated approach to fighting cancer and to ensure that research discoveries are translated into clinical and public health interventions that can be delivered to all who need them have been embraced by many private and public institutions, several of which have made commitments to programs and activities that are building blocks for this effort. 139 For example, the NAACCR is actively involved in extending its standardization activities beyond the cancer registry community to foster and contribute to a national health information structure.
In addition to the better application of existing knowledge, leaders in the scientific community forecast an era of unprecedented progress in cancer research through applying knowledge of the molecular and cellular mechanisms that underlie the initiation and progression of cancer. Areas of particular interest, highlighted in the NCI's research priorities, include seven strategic priority areas: molecular epidemiology; integrated cancer biology; the strategic development of cancer interventions; prevention, early detection, and prediction; an integrated clinical trials system; overcoming health disparities; and bioinformatics. 141 The development of imatinib mesylate for the treatment of CML is an example of a treatment breakthrough resulting from understanding the molecular abnormality involved in a particular type of cancer. 100 In addition to treatment advances, a better understanding of the basis of cancer has led to more effective prevention strategies, the development of improved tests for early detection, more precise diagnostic methods, and more powerful treatment approaches. Transdisciplinary research efforts have the potential to enhance our understanding of the interaction of genetic and environmental risk factors for tobacco addiction and obesity, leading to the improved prevention and treatment of the major cancer risk factors in the U.S. population. However, for research advances to impact cancer incidence and death rates, the translation of research discoveries to the widespread and equitable delivery of preventive and clinical services must be expedited.
In the 21st century, cancer surveillance will play a critical role in monitoring the nation's progress against cancer. The Annual Report to the Nation is just one facet of ongoing collaborations among the ACS, the CDC's NPCR and NCHS, the NCI's SEER Program, and the NAACCR. Through collaborative and coordinated initiatives and programs, these organizations are working to improve the comprehensiveness and quality of data used to focus cancer control efforts and track progress against cancer. In the future, the integrated and efficient exchange of standardized information among clinical, administrative, and public health data systems will enable better assessments of these successes in all populations and in all areas of the U.S.
